Post-acute COVID-19 Sequelae in Denmark

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHvidovre University Hospital

About this trial

Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase) can lead to impaired function in various organ systems, with a focus on the lungs, cardiovascular system, and kidneys. These three NCDs collectively impose a significant burden on individuals and society. Urgently, we need to understand the connection between COVID-19, PAP and NCDs, identifying robust biomarkers for early detection. This study examines PAP and associated risk factors, investigating the link between PAP and the heightened risk of lung, heart, and kidney complications. Utilizing data from a cohort of COVID-19 patients and a control group with respiratory diseases, the study aims to determine prevalence and risk ratios more precisely. The aim is to contribute to minimizing the risk of NCD development or exacerbation in current and future COVID-19 patients, enhancing our understanding of chronic disease development at the population leve

Eligibility criteria

Qualifiers

Has a blood sample in the clinical biobank related to the OBS-COVID index admission

Aged above 18 years at time of index-admission

Disqualifiers

Patients without a Danish personal identification number

Patients who do not understand or speak Danish

Trial design

Treatments tested in this trial

  • blood sample
  • Online questionaire

Treatment groups

800 Participants
are divided into 2 treatment groups

Sponsors and collaborators